Auriga Upgrades Protalix BioTherapeutics (PLX) to Buy
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.64 -3.3%
Rating Summary:
3 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 3 | Down: 5 | New: 34
Rating Summary:
3 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 3 | Down: 5 | New: 34
Join SI Premium – FREE
Auriga upgraded Protalix BioTherapeutics (NYSE: PLX) from Hold to Buy, price target raised from $8 to $9.
For an analyst ratings summary and ratings history on Protalix BioTherapeutics click here. For more ratings news on Protalix BioTherapeutics click here.
Shares of Protalix BioTherapeutics closed at $6.73 yesterday.
For an analyst ratings summary and ratings history on Protalix BioTherapeutics click here. For more ratings news on Protalix BioTherapeutics click here.
Shares of Protalix BioTherapeutics closed at $6.73 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Downgrades Bukit Asam Tbk PT (PTBA:IJ) to Underweight
- Adobe (ADBE) PT Raised to $255 at UBS Following Q3 Results
- UBS Upgrades Lovisa Holdings Ltd (LOV:AU) to Buy
Create E-mail Alert Related Categories
Analyst PT Change, UpgradesRelated Entities
AurigaSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
